Photodynamic Diagnostics and Noninvasive Bladder Cancer: Is It Cost-Effective in Long-Term Application? A Germany-Based Cost Analysis

Boyle, 2005, Cancer incidence and mortality in Europe, 2004, Ann Oncol, 16, 481, 10.1093/annonc/mdi098 Botteman, 2003, The health economics of bladder cancer: a comprehensive review of the published literature, Pharmacoeconomics, 21, 1315, 10.1007/BF03262330 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031 Hedelin, 2002, The cost of bladder tumour treatment and follow-up, Scand J Urol Nephrol, 36, 344, 10.1080/003655902320783845 Lotan, 2006, Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis, Cancer, 107, 982, 10.1002/cncr.22084 Jakse, 2004, A second-look TUR in T1 transitional cell carcinoma: Why?, Eur Urol, 45, 539, 10.1016/j.eururo.2003.12.016 Zaak, 2005, Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy, BJU Int, 96, 217, 10.1111/j.1464-410X.2005.05604.x D’Hallewin, 2002, Fluorescence detection of bladder cancer: a review, Eur Urol, 42, 417, 10.1016/S0302-2838(02)00402-5 Filbeck, 2002, Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors, J Urol, 168, 67, 10.1016/S0022-5347(05)64833-1 Filbeck, 2002, Do patients profit from 5-aminolevulinic acid induced fluorescence diagnosis in transurethral resection of bladder carcinoma?, Urology, 60, 1025, 10.1016/S0090-4295(02)01961-1 Orellana, 2002, Reform in German hospital funding system concerns doctors, Lancet, 359, 328, 10.1016/S0140-6736(02)07561-X Krukemeyer, 2004, Structural problems in the German hospital system, Cent Eur J Public Health, 12, 161 Daniltchenko, 2005, Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study, J Urol, 174, 2129, 10.1097/01.ju.0000181814.73466.14 Stenzl, 2001, Fluorescence assisted transurethral resection of bladder tumours: Is it cost effective?, Eur Urol, 39, 31 Oosterlinck, 2002, European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer, Eur Urol, 41, 105, 10.1016/S0302-2838(01)00026-4 Zaak, 2001, Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies, Urology, 57, 690, 10.1016/S0090-4295(00)01053-0 Svatek, 2005, Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?, Urology, 66, 65, 10.1016/j.urology.2005.02.003 Witjes, 2005, Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study, Eur Urol, 47, 319, 10.1016/j.eururo.2004.09.017 Loidl, 2005, Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: A new approach for bladder cancer detection and surveillance?, Eur Urol, 47, 323, 10.1016/j.eururo.2004.10.025